|
1.
|
|
16 p, 1.2 MB |
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab : A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
/
Reich, Kristian (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) ;
Bianchi, Luca (U.O.S.D. di Dermatologia Fondazione PTV Policlinico Tor Vergata, Rome, Italy) ;
Khemis, Abdallah (Polyclinique Saint George, Groupe KANTYS, Nice, France) ;
Maul, Julia-Tatjana (University of Zürich) ;
Tsianakas, Athanasios (Fachklinik Bad Bentheim, Bad Bentheim, Germany) ;
Schempp, Christoph M. (University of Freiburg, Germany) ;
Petersen, Kim (LEO Pharma A/S, Ballerup, Denmark) ;
Noergaard, Mia M. (LEO Pharma A/S, Ballerup, Denmark) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians' choice of treatment. [...]
2024 -  10.1007/s13555-023-01092-x
Dermatology and Therapy, Vol. 14 (february 2024) , p. 453-468
|
|
|
2.
|
|
10 p, 3.2 MB |
Multidimensional Data Encoding Based on Multicolor Microencapsulated Thermoresponsive Fluorescent Phase Change Materials
/
Otaegui, Jaume Ramon (Institut Català de Nanociència i Nanotecnologia) ;
Ruiz-Molina, Daniel (Institut Català de Nanociència i Nanotecnologia) ;
Hernando Campos, Jordi (Universitat Autònoma de Barcelona. Departament de Química) ;
Roscini, Claudio (Institut Català de Nanociència i Nanotecnologia)
Luminescent materials are emerging promising tools for digital data encoding due to their reduced cost, facile reading, robustness, and durability. For this, the use of fluorescent systems that combine multicolor emission with sensitivity to external stimuli will be highly desirable, as they can offer rewritable data encoding together with enhanced encryption security and storage density. [...]
2024 - 10.1002/adfm.202402510
Advanced Functional Materials, (2024) , art. 2402510
|
|
|
3.
|
|
23 p, 358.3 KB |
Feasibility of aerobic exercise in the subacute phase of recovery from traumatic brain injury : A case series
/
Morris, Timothy P. (Institut Germans Trias i Pujol. Institut Guttmann) ;
Costa Miserachs, David (Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States) ;
Rodriguez-Rajo, Pablo (Institut Germans Trias i Pujol. Institut Guttmann) ;
Finestres, Jordi (Institut Germans Trias i Pujol. Institut Guttmann) ;
Bernabeu Guitart, Montserrat (Institut Germans Trias i Pujol. Institut Guttmann) ;
Gomes-Osman, Joyce (Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States) ;
Pascual Leone, Álvaro (Institut Germans Trias i Pujol. Institut Guttmann) ;
Tormos-Muñoz, Jose Maria (Institut Germans Trias i Pujol. Institut Guttmann)
Background and purpose: Injuries associated with traumatic brain injury (TBI) are common and can complicate rehabilitation. The objective of this study is to examine the feasibility of introducing aerobic physical exercise programs into the subacute phase of multidisciplinary rehabilitation from moderate-to-severe TBI, which includes computerized cognitive training. [...]
2018 - 10.1097/NPT.0000000000000239
Journal of Neurologic Physical Therapy, Vol. 42 Núm. 4 (october 2018) , p. 268-275
|
|
|
4.
|
|
13 p, 2.9 MB |
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy
/
Statland, J.M. (University of Kansas Medical Center) ;
Campbell, C. (University of Western Ontario) ;
Desai, Urvi (Carolinas MDA Care Center) ;
Karam, C. (Oregon Health & Science University) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Guptill, J.T. (Duke University School of Medicine) ;
Korngut, L. (University of Calgary) ;
Genge, A. (Montreal Neurological Institute) ;
Tawil, R.N. (University of Rochester School of Medicine) ;
Elman, L. (University of Pennsylvania) ;
Joyce, N.C. (University of California Davis Medical Center) ;
Wagner, K.R. (Kennedy Krieger Institute) ;
Manousakis, G. (University of Minnesota) ;
Amato, A.A. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Butterfield, R.J. (University of Utah) ;
Shieh, P.B. (University of California Los Angeles) ;
Wicklund, M. (University of Colorado) ;
Gamez, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bodkin, C. (Indiana University School of Medicine) ;
Pestronk, A. (Washington University School of Medicine) ;
Weihl, C.C. (Washington University School of Medicine) ;
Vilchez-Padilla, J.J. (Hospital UIP La Fe. Neuromuscular Reference Centre) ;
Johnson, N.E. (Virginia Commonwealth University) ;
Mathews, K.D. (University of Iowa) ;
Miller, B. (Acceleron Pharma) ;
Leneus, A. (Acceleron Pharma) ;
Fowler, M. (Acceleron Pharma) ;
van de Rijn, M. (Acceleron Pharma) ;
Attie, K.M. (Acceleron Pharma)
Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies. In this study we evaluated whether locally acting ACE-083 could safely increase muscle volume and improve functional outcomes in adults with FSHD. [...]
2022 - 10.1002/mus.27558
Muscle & nerve, Vol. 66 Núm. 1 (july 2022) , p. 50-62
|
|
|
5.
|
|
9 p, 525.7 KB |
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
/
Spinner, Christoph D. (Technical University of Munich) ;
Felizarta, Franco (Office of Franco Felizarta) ;
Rizzardini, Giuliano (University of the Witwatersrand) ;
Philibert, Patrick (Hôpital Europen de Marseille) ;
Mitha, Essack (Newtown Clinical Research) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Stephan, Christoph J. (Universitätsklinikum Frankfurt) ;
Degrosky, Michelle (ViiV Healthcare) ;
Bainbridge, Veronica (GlaxoSmithKline) ;
Zhan, Joyce (GlaxoSmithKline) ;
Dumitrescu, Teodora Pene (GlaxoSmithKline) ;
Jeffrey, Jerry L. (ViiV Healthcare. Research Triangle Park) ;
Xu, Jianfeng (GlaxoSmithKline) ;
Halliday, Fiona (GlaxoSmithKline) ;
Gan, Jianjun (GlaxoSmithKline) ;
Johnson, Mark (ViiV Healthcare. Research Triangle Park) ;
Gartland, Martin (ViiV Healthcare. Research Triangle Park) ;
Joshi, Samit R. (ViiV Healthcare) ;
Lataillade, Max (ViiV Healthcare) ;
Universitat Autònoma de Barcelona
GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study evaluated antiviral effect, safety, tolerability, and PK of once-daily GSK'254 monotherapy administered with food (moderate-fat meal) in HIV-1-positive, treatment-naive adults. [...]
2022 - 10.1093/cid/ciab1065
Clinical Infectious Diseases, Vol. 75 Núm. 5 (january 2022) , p. 786-794
|
|
|
6.
|
|
|
7.
|
|
9 p, 582.7 KB |
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status : a GEICO phase II trial (ROLANDO study)
/
Perez-Fidalgo, J.A. (Hospital Clínic Universitari (València)) ;
Cortés, A. (Hospital Universitario Ramón y Cajal) ;
Guerra, E. (Hospital Universitario Ramón y Cajal) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Iglesias, M. (Hospital Son Llatzer) ;
Bohn Sarmiento, U. (Hospital Universitario de Gran Canaria Doctor Negrín) ;
Calvo García, E. (Hospital Universitario Virgen del Rocío) ;
Manso Sánchez, L. (Hospital Universitario 12 de Octubre) ;
Santaballa, A. (Hospital Universitari i Politècnic La Fe, València) ;
Oaknin, Ana (Hospital Universitari Vall d'Hebron) ;
Redondo, A. (Hospital Universitario La Paz) ;
Rubio, M.J. (Hospital Universitario Reina Sofia) ;
González-Martín, A. (Clínica Universidad de Navarra, Madrid) ;
Universitat Autònoma de Barcelona
There is limited evidence for the benefit of olaparib in platinum-resistant ovarian cancer (PROC) patients with BRCA wild-type tumors. This study investigated whether this combination of a DNA-damaging chemotherapy plus olaparib is effective in PROC regardless BRCA status. [...]
2021 - 10.1016/j.esmoop.2021.100212
ESMO open, Vol. 6 (july 2021)
|
|
|
8.
|
|
|
9.
|
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 - 10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
|
10.
|
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
